2024
Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act
Demkowicz P, Buck M, Nie J, Marks V, Wheeler S, Dinan M, Gross C, Leapman M. Changes in Facility Share of Medicaid-insured Patients With Urologic Cancers Following Implementation of the Patient Protection and Affordable Care Act. Urology 2024, 192: 19-27. PMID: 38901803, DOI: 10.1016/j.urology.2024.06.003.Peer-Reviewed Original ResearchFacility-level changesAffordable Care ActNon-expansion statesUrological cancer patientsProportion of patientsExpansion statesBaseline proportion of patientsUrologic cancer careHigh-income zip codesCancer patientsFactors associated with changesPre-post designCancer care centerPost-ACA periodMedicaid expansion statesMultivariate logistic regressionMedicaid-insured patientsCancer careUrological cancersZip codesCare ActMedicaid patientsMedicaidLogistic regressionCare centerImmunotherapy utilization patterns in patients with advanced cancer and autoimmune disease
Li H, Huntington S, Gross C, Wang S. Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease. PLOS ONE 2024, 19: e0300789. PMID: 38625861, PMCID: PMC11020359, DOI: 10.1371/journal.pone.0300789.Peer-Reviewed Original ResearchConceptsAutoimmune diseasesImmunotherapy cycleFirst-lineNon-small cell lung cancerAdvanced cancerFirst-line immunotherapyOverall treatment toleranceCell lung cancerRenal cell carcinomaRetrospective cohort studyAssociated with lower oddsAdvanced melanomaCell carcinomaTreatment toleranceAbsolute contraindicationImmunotherapyConsensus guidelinesImprove cancer survivalLung cancerCohort studyClinical variablesCancer patientsAcademic centersPatientsIncidence rate
2023
Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns.
Canavan M, Wang X, Ascha M, Miksad R, Showalter T, Calip G, Gross C, Adelson K. Survival analysis of patients treated at oncology practices with more aggressive end-of-life practice patterns. Journal Of Clinical Oncology 2023, 41: 6562-6562. DOI: 10.1200/jco.2023.41.16_suppl.6562.Peer-Reviewed Original ResearchReal-world overall survivalSystemic anticancer therapySurvival analysisNon-small cell lungCox proportional hazards modelPractice-level factorsRenal cell carcinomaProportional hazards modelCommon cancer typesDe-identified databaseElectronic health recordsAdvanced diseaseAdult patientsHazard ratioMetastatic diseaseMost patientsOverall survivalSurvival benefitSystemic treatmentAggressive endPrimary outcomeCell carcinomaCell lungPrimary exposureCancer patients
2020
Development and External Validation of a Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients
Gao S, Dosoretz A, Shafman T, Gross C, Yu J, Meadows H, Decker R, Mak R, Kann B. Development and External Validation of a Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e90. DOI: 10.1016/j.ijrobp.2020.07.1190.Peer-Reviewed Original ResearchThe association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC).
Gross C, Meyer C, Ogale S, Kent M, Wong W. The association between Medicaid insurance, biomarker testing, and outcomes in patients with advanced non-small cell lung cancer (aNSCLC). Journal Of Clinical Oncology 2020, 38: 89-89. DOI: 10.1200/jco.2020.38.29_suppl.89.Peer-Reviewed Original ResearchBiomarker-driven therapiesBiomarker testingEvidence of testingYear of diagnosisQuality cancer careUS cancer patientsLikelihood of testingDe-identified databaseEvidence of receiptEligible ptsOverall survivalAdjusted analysisContemporary cohortMedicaid insuranceRetrospective studyCancer careCancer patientsWorse outcomesCancer clinicHigh riskCommercial insurancePrivate insuranceAdvanced diagnosisTherapyDiagnosis
2019
An Externally Validated Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients
Gao S, Kann B, Dosoretz A, Shafman T, Gross C, Yu J, Decker R. An Externally Validated Nomogram to Predict Distant Metastases after Stereotactic Body Radiation Therapy in Early Stage Non-Small Cell Lung Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2019, 105: s145-s146. DOI: 10.1016/j.ijrobp.2019.06.146.Peer-Reviewed Original Research
2016
A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy
Stahl J, Ross R, Harder E, Mancini B, Soulos P, Dosoretz A, Finkelstein S, Shafman T, Husain Z, Evans S, Yu J, Gross C, Decker R. A Biologically Effective Dose of ≥105 Gy Is Associated With Improved Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: s174-s175. DOI: 10.1016/j.ijrobp.2016.06.438.Peer-Reviewed Original ResearchChanges in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy
Wang E, Wang S, Soulos P, Chen R, Kim S, Gross C, Yu J. Changes in quality of life after radiation therapy for localized prostate cancer after dissemination of intensity modulated radiation therapy. Journal Of Radiation Oncology 2016, 6: 295-300. DOI: 10.1007/s13566-016-0269-0.Peer-Reviewed Original ResearchExternal beam radiation therapyIntensity-modulated radiation therapyMental component scoreRadiation therapyProstate cancerEnd Results-Medicare Health Outcomes SurveyEra of IMRTComponent scoresImproved health-related qualityNonmetastatic prostate cancerPhysical component scoreHealth-related qualityHealth Outcomes SurveyStandard of careProstate cancer patientsExternal beam radiotherapyBeam radiation therapyQuality of lifeMethodsThe SurveillanceElderly patientsHRQOL measurementCancer patientsOutcome SurveyBeam radiotherapyLater eraComplex association between social support and chemotherapy-related toxicities in older cancer patients.
Shahrokni A, Sun C, Tew W, Mohile S, Owusu C, Klepin H, Gross C, Lichtman S, Gajra A, Katheria V, Cohen H, Hurria A. Complex association between social support and chemotherapy-related toxicities in older cancer patients. Journal Of Clinical Oncology 2016, 34: 10036-10036. DOI: 10.1200/jco.2016.34.15_suppl.10036.Peer-Reviewed Original Research
2015
Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study
Wang R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia in Prostate Cancer Patients after Radiotherapy, a Population-Based Study. Blood 2015, 126: 3295. DOI: 10.1182/blood.v126.23.3295.3295.Peer-Reviewed Original ResearchMDS/AMLProstate cancer patientsIntensity-modulated radiotherapyProstate cancer diagnosisImpact of radiotherapyCancer patientsMyelodysplastic syndromeProstate cancerMyeloid malignanciesSecond malignanciesHazard ratioCancer diagnosisRadiation modalitiesEnd Results-Medicare databaseElderly prostate cancer patientsRisk of MDSMultivariate modelRetrospective cohort studyRole of radiotherapyElixhauser comorbidity scoreAcute myeloid leukemia diagnosisHistory of anemiaAcute myeloid leukemiaEnd of studyExternal beam radiotherapySecondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study
Zeidan A, Long J, Wang R, Yu J, Hall J, Abel G, Gore S, Gross C, Ma X, Davidoff A. Secondary Myeloid Neoplasms in Older Women with Breast Cancer after Radiotherapy: A Population-Based Study. Blood 2015, 126: 1676. DOI: 10.1182/blood.v126.23.1676.1676.Peer-Reviewed Original ResearchTherapy-related myeloid neoplasmsMDS/acute myeloid leukemiaSingle-modality radiotherapyAcute myeloid leukemiaBreast cancer patientsMonths of diagnosisEarly breast cancerCompeting-risk analysisMyelodysplastic syndromeBreast cancerCancer patientsBreast cancer diagnosisRisk factorsMyeloid neoplasmsRadiation therapyAML/myelodysplastic syndromeFemale breast cancer patientsNational Cancer Institute's SurveillanceRadiotherapy-treated patientsReceipt of radiotherapySecondary myeloid neoplasmsRetrospective cohort studyCancer diagnosisNumber of comorbiditiesBetter overall survival80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDY
Wane R, Zeidan A, Soulos P, Yu J, Davidoff A, Gore S, Gross C, Ma X. 80 SUBSEQUENT MYELODYSPLASTIC SYNDROMES IN PROSTATE CANCER PATIENTS AFTER RADIOTHERAPY, A POPULATION-BASED STUDY. Leukemia Research 2015, 39: s39. DOI: 10.1016/s0145-2126(15)30081-3.Peer-Reviewed Original Research
2013
Factors associated with unplanned breast cancer readmissions.
Gavankar C, Gross C, Lilenbaum R, Chagpar A. Factors associated with unplanned breast cancer readmissions. Journal Of Clinical Oncology 2013, 31: 131-131. DOI: 10.1200/jco.2013.31.31_suppl.131.Peer-Reviewed Original ResearchBreast cancer patientsCancer patientsCharlson/Deyo scoreNational Cancer DatabaseUnplanned hospital readmissionLymph node statusAmerican Cancer SocietyDeyo scoreHospital readmissionMargin statusNode statusTumor sizeInsurance statusCancer DatabaseCancer casesCancer SocietyAmerican CollegePatientsMultivariate analysisReadmissionFacility typeUHRThe Dissemination of New Technologies and Temporal Trends in Curative Therapy for Prostate Cancer Patients With Low Likelihood of Clinical Benefit
Raldow A, Presley C, Yu J, Cramer L, Soulos P, Long J, Makarov D, Gross C. The Dissemination of New Technologies and Temporal Trends in Curative Therapy for Prostate Cancer Patients With Low Likelihood of Clinical Benefit. International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s177-s178. DOI: 10.1016/j.ijrobp.2013.06.459.Peer-Reviewed Original ResearchHealth practices and behaviors of childhood cancer survivors not attending a comprehensive survivor clinic.
Iyer N, Mitchell H, Gross C, Ma X, Kadan-Lottick N. Health practices and behaviors of childhood cancer survivors not attending a comprehensive survivor clinic. Journal Of Clinical Oncology 2013, 31: 10063-10063. DOI: 10.1200/jco.2013.31.15_suppl.10063.Peer-Reviewed Original ResearchSurvivor clinicSurvivorship careHealth practicesCancer Survivor ClinicHealth communication preferencesChildhood cancer survivorsPrimary care physiciansChildhood cancer patientsPhysical activity resultsWeekly physical activityMajority of survivorsOB/GYNsUtilization of servicesActive smokersTumor RegistryCare physiciansCancer survivorsCDC guidelinesPediatric oncologistsInvasive cancerMean ageCancer patientsCDC recommendationsPrimary careVegetable intake
2012
Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT.
Yu J, Soulos P, Cramer L, Roberts K, Herrin J, Potosky A, Gross C. Proton radiotherapy for prostate cancer in the Medicare population: Patterns of care and comparison of early toxicity with IMRT. Journal Of Clinical Oncology 2012, 30: 4651-4651. DOI: 10.1200/jco.2012.30.15_suppl.4651.Peer-Reviewed Original ResearchProstate cancer patientsSix monthsShort-term toxicityOne-yearCancer patientsPRT patientsProstate cancerProton radiotherapyLogistic regressionTreatment-related complicationsOne-year outcomesCumulative complication rateMultivariable logistic regressionPatient-reported outcomesPatterns of careConditional logistic regressionHigher socioeconomic statusGU complicationsGU toxicityComplication rateEarly toxicityDiagnosis codesLong-term effectsRadiation therapyMedicare populationThe influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit.
Yu J, Aneja S, Makarov D, Roberts K, Gross C. The influence of physician densities and patient characteristics on the decision to treat prostate cancer patients with varying clinical benefit. Journal Of Clinical Oncology 2012, 30: 19-19. DOI: 10.1200/jco.2012.30.5_suppl.19.Peer-Reviewed Original ResearchHealth system factorsHealth service areasCurative therapyUrologist densityClinical benefitProstate cancerRadiation oncologistsPhysician densitySystem factorsRadiation oncologist densityEnd Results (SEER) databaseLower likelihoodReceipt of treatmentMarital statusProstate cancer patientsHigher likelihoodLogistic regression modelsArea Resource FilePatient characteristicsPatient factorsInitial treatmentResults databasePatient populationCancer patientsProper therapy
2011
The Influence of Physician Densities and Patient Characteristics on the Decision to Treat Prostate Cancer Patients with Varying Clinical Benefit
Aneja S, Makarov D, Gross C, Roberts K, Yu J. The Influence of Physician Densities and Patient Characteristics on the Decision to Treat Prostate Cancer Patients with Varying Clinical Benefit. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s553. DOI: 10.1016/j.ijrobp.2011.06.871.Peer-Reviewed Original Research
2010
Head and Neck Cancer (HNC) Patients Undergoing Intensity Modulated Radiation Therapy (IMRT) Have Fewer Subsequent Days of Hospitalization (DOH) than Do Patients Undergoing Conventional Radiation Therapy (CRT) in the SEER-Medicare Linked Database
Gross C, Soulos P, Sharma R, Makarov D, Decker R, Smith B, Desai R, Cramer L, Yu J. Head and Neck Cancer (HNC) Patients Undergoing Intensity Modulated Radiation Therapy (IMRT) Have Fewer Subsequent Days of Hospitalization (DOH) than Do Patients Undergoing Conventional Radiation Therapy (CRT) in the SEER-Medicare Linked Database. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s445. DOI: 10.1016/j.ijrobp.2010.07.1045.Peer-Reviewed Original ResearchHead and Neck Cancer (HNC) Patients Undergoing Primary Radiation with Intensity Modulated Radiation Therapy (IMRT) Demonstrate Improved Overall Survival (OS) Compared to Those Undergoing Conventional Radiation Therapy (CRT) in the SEER-Medicare Linked Database
Yu J, Soulos P, Sharma R, Makarov D, Decker R, Smith B, Desai R, Cramer L, Gross C. Head and Neck Cancer (HNC) Patients Undergoing Primary Radiation with Intensity Modulated Radiation Therapy (IMRT) Demonstrate Improved Overall Survival (OS) Compared to Those Undergoing Conventional Radiation Therapy (CRT) in the SEER-Medicare Linked Database. International Journal Of Radiation Oncology • Biology • Physics 2010, 78: s459. DOI: 10.1016/j.ijrobp.2010.07.1077.Peer-Reviewed Original Research